Literature DB >> 8335917

Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.

L K Bockenstedt1, E Fikrig, S W Barthold, F S Kantor, R A Flavell.   

Abstract

The murine immune response to Borrelia burgdorferi (Bb), the etiologic agent of Lyme disease, is characterized by the development of antibodies reactive with the outer surface protein (Osp) A. It has been demonstrated that passive immunization of mice with at least some Osp A antibodies, including an Osp A mAb (CIII.78) that binds to a conformational epitope in the carboxyl-terminus of Osp A, provides protection against Bb challenge. Active immunization of mice with Osp A also confers protection, making Osp A a candidate for a vaccine Ag. To determine the regions of the Osp A protein that can elicit protective immunity, we immunized boosted mice with overlapping recombinant truncated fragments of Osp A, then challenged them with Bb. All groups of mice developed IgG Osp A antibodies detectable by immunoblotting with sera diluted at least 5000-fold. As expected, vaccination with full-length recombinant Osp A protected mice from challenge infection. In contrast, none of the mice vaccinated with the truncated Osp A proteins demonstrated immunity, even those immunized with an Osp A fragment binding the neutralizing mAb CIII.78. Osp A antibodies contained in the truncated Osp A antisera also failed to immunoprecipitate in vitro translated full-length Osp A and did not bind, as demonstrated by indirect immunofluorescence, to live or acetone-fixed Bb. Taken together, these results suggest that neutralizing Osp A antibodies are induced by vaccination with the full-length recombinant Osp A protein but not by vaccination with recombinant fragments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335917

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  W T Golde; J Piesman; M C Dolan; M Kramer; P Hauser; Y Lobet; C Capiau; P Desmons; P Voet; D Dearwester; J C Frantz
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Design of a broadly reactive Lyme disease vaccine.

Authors:  Heather D Kamp; Kurt A Swanson; Ronnie R Wei; Pradeep K Dhal; Ram Dharanipragada; Aurelie Kern; Bijaya Sharma; Radek Sima; Ondrej Hajdusek; Linden T Hu; Chih-Jen Wei; Gary J Nabel
Journal:  NPJ Vaccines       Date:  2020-05-01       Impact factor: 7.344

3.  Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice.

Authors:  L K Bockenstedt; E Hodzic; S Feng; K W Bourrel; A de Silva; R R Montgomery; E Fikrig; J D Radolf; S W Barthold
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

4.  Identification of an immunologically important hypervariable domain of major outer surface protein A of Borrelia burgdorferi.

Authors:  B C McGrath; J J Dunn; G Gorgone; D Guttman; D Dykhuizen; B J Luft
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

5.  Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.

Authors:  M Dunne; B K al-Ramadi; S W Barthold; R A Flavell; E Fikrig
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

6.  Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey.

Authors:  M K Aydintug; Y Gu; M T Philipp
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

7.  Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.

Authors:  S D Lovrich; S M Callister; B K DuChateau; L C Lim; J Winfrey; S P Day; R F Schell
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

8.  An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.

Authors:  Theresa A Willett; Abbie L Meyer; Eric L Brown; Brigitte T Huber
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

9.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

10.  Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.

Authors:  Jerilyn R Izac; Lee D Oliver; Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2017-05-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.